慢性心力衰竭中的胰岛素类生长因子结合蛋白-7度:来自EMPEROR计划的结果
João Pedro Ferreira1,2, Milton Packer3, Naveed Sattar4
1Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, Nancy, France; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
European journal of heart failure
|April 8, 2024
概括
胰岛素样生长因子结合蛋白-7 (IGFBP7) 水平升高,预测心力衰竭患者的心脏结结果会更差,不管喷射分数如何. 恩帕格利弗洛辛治疗没有改变IGFBP7度.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 生物标志物研究 生物标志物研究
背景情况:
- 胰岛素类生长因子结合蛋白-7 (IGFBP7) 是组织衰老的生物标志物,与心脏脏疾病有关.
- 在心力衰竭 (HF) 频谱中,IGFBP7的预后值需要进一步阐明.
研究的目的:
- 调查IGFBP7水平与HF患者的心脏结局之间的关联,无论EF.
- 评估empagliflozin治疗对HF患者IGFBP7度的影响.
主要方法:
- 在1125名来自EMPEROR-Reduced和EMPEROR-Preserved试验的参与者中测量了IGFBP7.
- 考克斯回归模型被用来评估基线IGFBP7三位体与HF住院或心血管死亡风险以及复合结点之间的关系.
- 针对临床变量,N终端亲B型性尿素和高灵敏度心脏素T进行了调整.
主要成果:
- 较高的基线IGFBP7三角动物与更高风险的临床形状有关.
- 较高的IGFBP7水平独立地预测了HF住院或心血管死亡的风险增加 (HR 2.00) 和脏复合终点 (HR 4.66) 的风险增加,无论EF.
- 恩帕格利弗洛辛治疗在12周或52周后没有显著改变IGFBP7水平,但它降低了心血管死亡/HF住院的风险,独立于基线IGFBP7.
结论:
- 在整个EF频谱的心力衰竭患者中,IGFBP7度与不良心脏脏结局有关,即使调整了已知的生物标志物.
- 恩帕格利弗洛辛证明对心血管和的结果有有益影响,独立于IGFBP7水平,并没有随着时间的推移显著改变IGFBP7度.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
01:26Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577